One of the biggest challenges in cancer treatment is something called “drug resistance.” This happens when cancer cells stop ...
Zacks Investment Research on MSN
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved label expansion of its PD-1 ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DPTX3186, a first in class oral condensate ...
The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...
Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
Many dedicated dog parents like @hayleyglatfelter know what it's like to rehabilitate a sick dog, but this brave woman has seen her even braver pup, Gideon, endure so much this year. Earlier this fall ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min See which companies topped the ...
Dear Dr. Roach: I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I'm writing because during a routine dental cleaning, my dentist noticed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback